Susan H. Fox
YOU?
Author Swipe
View article: Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease
Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease Open
INTRODUCTION Currently, our ability to predict cognitive decline in Parkinson's disease is limited. METHODS In 234 dementia‐free PD patients, cognitive profiles at baseline were determined using cluster analysis and longitudinal associatio…
View article: Segmental and Multifocal Isolated Dystonias: Similarities and Differences
Segmental and Multifocal Isolated Dystonias: Similarities and Differences Open
Background Whether the traditional distinction between segmental and multifocal dystonia is clinically or scientifically useful remains unclear. Objective To evaluate whether idiopathic isolated adult‐onset segmental and multifocal dystoni…
View article: Surgical removal of implanted microchips to correct <scp>MRI</scp> susceptibility artifacts in mice
Surgical removal of implanted microchips to correct <span>MRI</span> susceptibility artifacts in mice Open
Purpose Implanted microchips are becoming increasingly common in research for animal identification and have been adopted by commercial vendors for some mouse strains. However, they often contain metal components, which generate magnetic s…
View article: Neuroinflammation distinguishes HLA haplotypes in progressive supranuclear palsy
Neuroinflammation distinguishes HLA haplotypes in progressive supranuclear palsy Open
Objectives Progressive supranuclear palsy (PSP) is a neurodegenerative 4R tauopathy clinically presenting with atypical parkinsonism or cognitive behavioral changes and a relatively uniform neuropathology. We recently identified rare HLA h…
View article: The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy
The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy Open
Background and Objectives Progressive supranuclear paralysis (PSP) is an atypical parkinsonian disorder associated with oculomotor features, motor disturbances, along with cognitive problems and neuropsychiatric symptoms. Quality of life (…
View article: Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy
Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy Open
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by four-repeat (4R) tau protein deposition. The substantia nigra (SN) and midbrain tegmentum nuclei (MBT) are consistently affected. Lymphocyte infiltrates …
View article: Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy
Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy Open
Our study suggests that epitopes within the tau peptide may bind to HLA alleles that are found in a subset of PSP patients supporting the notion of an autoimmune pathophysiological component. These findings have implications for subtyping …
View article: Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review Open
Objective To update evidence‐based medicine recommendations for treating motor fluctuations of Parkinson's disease (PD). Background The International Parkinson and Movement Disorder Society (MDS) Evidence Based Medicine in Movement Disorde…
View article: Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy
Investigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy Open
Objectives Progressive supranuclear palsy (PSP) is a neurodegenerative disease showing pathological tau accumulation in subcortical neurons and glial cells. The human leukocyte antigen ( HLA ) locus on chromosome 6 is a polymorphic region …
View article: External Factors Modulating Pain and Pain‐Related Functional Impairment in Cervical Dystonia
External Factors Modulating Pain and Pain‐Related Functional Impairment in Cervical Dystonia Open
Background Little is known about factors modulating pain and pain‐related functional impairment in isolated cervical dystonia (CD). Objective The aim was to assess the prevalence and interrelationship between pain‐modulating factors and pa…
View article: Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear Palsy
Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear Palsy Open
This study discusses 4-repeat tau seeding in the skin of patients with progressive supranuclear palsy.
View article: The LRRK2 p.L1795F variant causes Parkinson’s disease in the Europeanpopulation
The LRRK2 p.L1795F variant causes Parkinson’s disease in the Europeanpopulation Open
Pathogenic variants in the LRRK2 gene represent the most common cause of autosomal dominant Parkinson’s disease (PD) worldwide. We identified the LRRK2 p.L1795F variant in 14 White/European ancestry PD patients, including two families with…
View article: Outcome Selection for Research Studies in Movement Disorders
Outcome Selection for Research Studies in Movement Disorders Open
Choosing the correct outcome measure for any clinical research study in the field of movement disorders depends on the disease being studied and the research question being asked. The clinical features of the movement disorder will impact …
View article: P.022 Gender disparity in canadian institutes of health research funding within neurology
P.022 Gender disparity in canadian institutes of health research funding within neurology Open
Background: Despite efforts to advance equity, women face gender-based barriers in research, including fewer senior authorship and grant opportunities. We examined gender disparities in Canadian Institutes of Health Research (CIHR) funding…
View article: Advice to People with Parkinson’s in My Clinic: Cannabis
Advice to People with Parkinson’s in My Clinic: Cannabis Open
Cannabis (in all the varied methods of delivery) continues to garner significant attention as a potential therapeutic intervention for neurodegenerative disorders, including Parkinson’s disease (PD). The recent legalization of personal use…
View article: Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy
Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy Open
Objectives To evaluate the effect of Alzheimer's disease (AD) ‐related biomarker change on clinical features, brain atrophy and functional connectivity of patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). …
View article: Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative Open
In 2011, the UK medical research charity Cure Parkinson’s set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson’s disease (PD). The f…
View article: Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia Open
This study provides Class I evidence that in adults with moderate-to-severe idiopathic cervical dystonia, DAXI reduces dystonia more effectively than placebo.